Greenville Hospital System Cancer Center — Greenville, South Carolina

Greenville Hospital System Cancer Center is a clinical research site located in Greenville, South Carolina, United States 29605.

Crixeo Clinical Trials Trust Score: 89/100 (GOOD). This profile has not yet been claimed by the site owner.

Greenville Hospital System Cancer Center has participated in 21 clinical trials.

Therapeutic areas: Lung Cancer, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms.

Sponsors: Alliance for Clinical Trials in Oncology, Children's Oncology Group, Radiation Therapy Oncology Group.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Greenville

Browse all research sites in South Carolina · View every site in Greenville

Sponsor Feasibility Report

Trust Score: 89/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Greenville Hospital System Cancer Center?

Greenville Hospital System Cancer Center has a Crixeo Trust Score of 89/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Greenville Hospital System Cancer Center conducted?

Greenville Hospital System Cancer Center has 21 clinical trials on record. Their work covers Lung Cancer, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms.

Is Greenville Hospital System Cancer Center accredited by Crixeo Clinical Trials?

Greenville Hospital System Cancer Center has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Greenville Hospital System Cancer Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.